Skip to main content
OpenTrials
Completed

NCT Number: NCT06659224

The Risk of Acute Myeloid Leukaemia in Patients With Ewing's Sarcoma

Ewing's sarcoma is an uncommon yet vital malignancy of bone. It demonstrates a predilection for the pediatric and young adult population. Chemotherapy is considered an important treatment modality for Ewing's sarcoma. However, the development of therapy-related leukemia, especially acute myeloid leukemia following treatment, is attributed to the use of substances such as alkylating agents and topoisomerase inhibitors which are genotoxic. There is a very few studies elaborating on the incidence rates of such complications. So, our aim is to quantify the risk of developing acute myeloid leukemia in Ewing sarcoma patients and provide an updated evidence to the literature.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Myeloid Leukemia (AML) Ewing Sarcoma Hematologic Diseases Hemic and Lymphatic Diseases Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Neoplasms Neoplasms by Histologic Type Neoplasms, Bone Tissue Neoplasms, Connective Tissue Neoplasms, Connective and Soft Tissue Osteosarcoma Sarcoma Sarcoma, Ewing

Sex eligibility

All sexes

Study type

Observational

Primary location

Suez Canal University

Ismailia, 41512, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients diagnosed with Ewing sarcoma
  • Latency exclusion period of 6 months
  • Sequence 0 or 1

Exclusion criteria

  • patients lacking age documentation or age reported only on death certificates or autopsies

Treatment and study plan

Primary outcomes

  1. The standardized incidence ratio and excess risk of developing acute myeloid leukemia in Ewing's sarcoma patients

    Time frame: from Jan, 2000 till Dec, 2021

    The surveillance, epidemiology and End Results (SEER) database was used to calculate the standardized incidence ratio (SIR) as Observed/Expected (O/E) and calculated the excess absolute risk for acute myeloid leukemia in Ewing's sarcoma patients.

Secondary outcomes

  1. The standardized incidence ratio and excess risk of second primary malignancies in Ewing's sarcoma patients across different racial groups

    Time frame: from Jan, 2000 till Dec, 2021

  2. The standardized incidence ratio and excess risk of second primary malignancies in Ewing's sarcoma patients between different stages

    Time frame: from Jan, 2000 till Dec, 2021

Sponsors and collaborators

Lead sponsor

asmaa salama ibrahim

Other

Registry information

Official study title

The Risk of Developing Acute Myeloid Leukaemia in Patients With Ewing's Sarcoma: A SEER-based Study

Important dates

Study start
2000
Primary completion
2021
Study completion
2021
First posted
Oct 26, 2024
Registry last updated
Jul 23, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.